Contact

Crown Bioscience Expands UK Facilities to Enable Growth of In Vivo Services

Upgraded facility increases capacity for in vivo services by 30 percent and adds high frequency ultrasound capabilities to the Company’s preclinical capabilities

Topics: Corporate

KBI Biopharma Completes Eurofins DiscoverX Products Specialized Bioassay Certification Program

Companies will work together on critical componentsthat canaccelerateclient-sponsored validation programs through downstream drug development

FREMONT, Calif. and DURHAM, N.C.October 11, 2021Eurofins DiscoverX Products,LLC(Eurofins DiscoverX),an industryleader in assays for drug discovery, development, and QC lot release, announced today the expansion of its Bioassay Certification Program through itscertification of KBI Biopharma, Inc. (KBI), a JSR Life Sciences company. KBI is among a specialized group of companies enabled to design workflows and implement Eurofins DiscoverX cell-based assays for multiple client-sponsored validation programs using DiscoverX’s PathHunter®technology platform to deliver highly reproducible potency lot release assays under GLP/GMP conditions.

“We are pleased to receive this certification from Eurofins DiscoverX and to be part of the important work the company is doing to fully leverage the utility of functional cell-based assays in biologics drug development,” said Dirk Lange, President and CEO, KBI Biopharma. “This collaboration reflects KBI’s commitment to rapidly accelerate each client’s drug development program, and we look forward to working with DiscoverX to offer the best scientific solutions to provide world-class results in downstream drug development.”

Demonstrations of potency with specialized, relevant cell-based assays are an integral component of the drug development process. Drug developersmust prove that their product candidates are safe and effective (potent). With potency assays playing acritical part of this process, regulators often require the use of functional, cell-based mechanism of action (MOA)-reflective assays that mimic a physiologically relevant environment for potency lot-release studies. The simplicity of the Eurofins DiscoverX PathHunter assay platform, coupled with its broad menu of assays, makes it an attractive platform for pharma and biotech companies to advance their molecules toward regulatory filings.

The advantage of expanding the Bioassay Certification Program, Eurofins DiscoverX leaders say, is that it offers a potent new tool in meeting the needs of biopharma clients seeking CROs and CDMOs that can run its bioassay potency assays when moving their drug product downstream through the development process. Currently, Eurofins DiscoverX includes over 24 qualified bioassays and 36 target-based bioassays that are implemented in global pharma and biotech companies.

Topics: Corporate

Crown Bioscience Launches ‘3D Ex Vivo Patient Tissue Platform’ to Improve Response Predictability to Immuno-Oncology Drug Candidates

Platform combining phenotypic high content imaging analysis and three-dimensional models of fresh patient tumors to provide relevant analysis of drug responses that can inform candidate selection and clinical program design

Topics: RR & IVD

MBL to Distribute Qkine’s Animal-free Growth Factors and Cytokines

Tokyo, Japan - September 30, 2021 - Medical & Biological Laboratories Co., Ltd. (MBL), a JSR Life Sciences Company, has signed a distributor agreement with Qkine Ltd. for sale of products in Japan. 

Topics: RR & IVD

MBL establishes a new R&D and manufacturing site for in vitro diagnostic products and services in Shenzhen, China

Shenzhen, China - September 17, 2021 - Medical and Biological Laboratories Co., Ltd. (President & CEO: Kimimasa Yamada, “MBL”), a JSR Life Sciences Company, announced that its subsidiary MBL Shenzhen Biotech Co., Ltd. (“MBLS”) has been established in full-scale operation as a new R&D and manufacturing site for in vitro diagnostic products and services in China.

MBL Launches New Automated Analyzer Kit to Quickly Detect Neutralizing Antibodies Against SARS-CoV-2

Kit will help with understanding immune status of COVID-19 patients and promote research on vaccine efficacy

Topics: RR & IVD

MBL International Launches QuickSwitch™ Class II Custom MHC Tetramer Kits

Woburn, MA – July 28, 2021 – MBL International, a JSR Life Sciences company, recently announced commercial availability of QuickSwitch™ Class II Custom MHC Tetramer Kits. QuickSwitch kits for Class II MHC Tetramers for analysis of CD4+ T cells have been created to meet the needs of scientists looking for better understanding of the CD4+ T cell responses.

Topics: RR & IVD

Crown Bioscience Invests in Commercial Leadership

New Vice President to lead North America and Europe Business Development

Topics: Corporate

Selexis and KBI Biopharma Enter into Agreements with Immatics for Integrated Approach to Advance Immatics TCR Bispecific Program Towards IND

Geneva, Switzerland, and Durham, NC – June 29, 2021  – Selexis SA and KBI Biopharma (KBI), both JSR Life Sciences companies, announced today that they have signed service agreements with Immatics N.V. (NASDAQ: IMTX; “Immatics”), a clinical-stage biopharmaceutical company active in the discovery and development of T cell redirecting cancer immunotherapies. The agreements focus on using integrated services from Selexis and KBI as part of Immatics’ development of TCR Bispecifics, called TCER® (T Cell Engaging Receptors), that simultaneously recruit, activate and stimulate the patient’s own T cells to detect, target and attack tumor cells. Under the agreements, Selexis will utilize its SUREtechnology Platform™ and KBI will leverage its advanced analytics, process, formulation and cGMP manufacturing for Immatics’ IMA402 program. 

Topics: Corporate

KBI Biopharma Enters Commercial Manufacturing Agreement with AM-Pharma to Prepare for the Commercial Launch of Lead Program in Acute Kidney Disease

Agreement supports future commercial manufacturing for AM-Pharma’s recombinant alkaline phosphatase program

Utrecht, The Netherlands and DURHAM, NC – June 17, 2021 – KBI Biopharma, Inc. (KBI), a JSR Life Sciences company, and AM-Pharma, an emerging leader focused on the development of therapeutics that protect organ function in patients with severe medical conditions, have signed a commercial manufacturing agreement to advance AM-Pharma’s recombinant human Alkaline Phosphatase (recAP) program towards commercialization. AM-Pharma is developing recAP for the potential treatment of Sepsis-Associated Acute Kidney Injury (SA-AKI). 

Topics: Corporate

CrownBio Acquires OcellO B.V. to Expand Its Preclinical In Vitro Drug Development Service Offerings

Acquisition augments CrownBio’s preclinical in vitro service platforms, adding high content imaging and advanced tumor organoid analytics to three-dimensional immuno-oncology drug assays

San Diego, California, May 5, 2021 – Crown Bioscience (CrownBio), a JSR Life Sciences company and leader in preclinical services that help biopharmaceutical companies accelerate new drug development programs, has acquired OcellO B.V., a privately owned contract research

Topics: Corporate

JSR Life Sciences Launches Corporate Venture Fund to Foster Investment in New Companies and Innovative Technologies

Company Appoints Seasoned Life Science Investment and Business Development Executive
Dr. Jason Yuanxin Zhang to Lead the Fund

SUNNYVALE, California, March 23, 2021  JSR Life Sciences, LLC today announced the launch of its ‘JSR Life Sciences Corporate Venture Fund.’ As part of a continued effort to identify and accelerate novel therapies and innovative technologies, JSR will leverage the new fund to invest in multiple deals within the next few years. 

Topics: Corporate

JSR Life Sciences Completes Integration of MBL into its Family of Companies

SUNNYVALE, California, March 16, 2021 – JSR Life Sciences, LLC announced that the JSR Corporation has finalized the acquisition of all outstanding shares in MEDICAL & BIOLOGICAL LABORATORIES CO., LTD. (MBL). As a result, MBL is a wholly owned subsidiary and affiliate of the JSR Life Sciences family.  

Topics: Corporate

CrownBio and JSR Life Sciences Partner with Cambridge Quantum Computing to Leverage Quantum Machine Learning for Novel Cancer Treatment Biomarker Discovery

The partnership is one of the first commercial applications of quantum technology for bioinformatics

SUNNYVALE, California, CAMBRIDGE, UNITED KINGDOM, February 24, 2021 – Crown Bioscience (CrownBio), JSR Life Sciences and Cambridge Quantum Computing (CQC) today announced a partnership agreement to explore the application of quantum technology to drive the identification of multi-gene biomarker discovery for oncology drug discovery.

Topics: Corporate

KBI Biopharma Expands US Operations with New $150 Million Commercial Manufacturing Facility Based in RTP, North Carolina

140,000-square-foot facility will create more than 200 highly specialized manufacturing jobs to support KBI’s commercialization pipeline

JSR Life Sciences Expands its European Gene-to-GMP Biologics Manufacturing Facilities for Selexis and KBI Biopharma in Geneva, Switzerland

SUNNYVALE, California, October 20, 2020 – JSR Life Sciences, LLC today announced that it is increasing its European footprint with a newly expanded, state-of-the-art facility that will co-locate primary European operations for its affiliate companies KBI Biopharma and Selexis SA. The two companies combined will occupy 8,700 square meters in the Stellar 32 campus within Geneva’s ZIPLO (Industrial Zone Plan-les-Ouates). KBI Biopharma’s expanded facility will enable the Company to offer clinical cGMP biologics bulk drug substance manufacturing for European clients. Selexis’ new workspaces will allow the Company to meet the increasing demand for its highly specialized mammalian cell line development technologies and services. Together, the companies anticipate creating more than 250 new highly technical jobs in the new facilities.

Topics: Corporate

Crown Bioscience Invests in Process Excellence with the Appointment of New Vice President of Global Quality

San Diego, Calif - October 8, 2020 - Crown Bioscience today announces the appointment of Pam Shang as vice president for global quality. Mrs. Shang will be instrumental in further enhancing global quality across the company, leveraging her deep expertise in implementing quality systems for pharma and biotechnology clients including in GLP, GMP and other regulated environments.

Topics: Corporate

Igyxos and Selexis Enter Service Agreement to Advance Igyxos’ First-In-Class Monoclonal Antibody for the Treatment of Human Infertility

Geneva, Switzerland, and Nouzilly, France - September 2, 2020 - Selexis SA and Igyxos announced today that they have entered into a service agreement to develop Igyxos’ first-in-class monoclonal antibody (mAb) drug candidate for the treatment of human infertility. Under the agreement, Igyxos will utilize Selexis’ proprietary SUREtechnology Platform™ to rapidly develop the research cell banks (RCBs) necessary to advance the program to human trials.

Globally, infertility affects approximately 100 million women and men.[1],[2]  In many cases, infertility is related to disorder in gonadotropins, which are hormones responsible for regulating the reproductive cycle. Therapeutic gonadotropins to treat infertility have been the standard of care since the 1960s. By developing a first-in-class mAb that boosts the bioactivity of endogenous and exogenous gonadotropins, Igyxos aims to significantly improve the therapeutic management of men and women suffering from infertility.

“Selexis is thrilled to play a part in Igyxos’ novel therapeutic approach to male and female infertility with an effective treatment that may overcome the long-standing challenges of current methods of addressing the issue,” said Yemi Onakunle, PhD, MBA, Selexis chief business officer. “As experts in cell line development, we are able to quickly and cost-effectively deliver the high-expressing, stable and production-ready research cell banks necessary to help Igyxos reach the clinic faster and gain a competitive edge. We look forward to embarking upon this exciting collaboration.”

Current infertility management remains unsatisfactory with low success rates (only 50% of treated couples have a child after four cycles of hormonal treatments on average), expensive and cumbersome medical treatment protocols with gonadotropins (several injections per week for up to 2 years in men) and low compliance (30% of patients stop during treatment).

“30 million men and 70 million women suffer from infertility worldwide, yet the prospect of a successful outcome remains limited due to a treatment landscape plagued by low success rates, challenging medical treatment protocols and low compliance,” said Pierre-Henry Longeray, CEO at Igyxos. “At Igyxos, we are working tirelessly to bring a new and long-overdue therapeutic option to address this important issue. With Selexis’ track record of success and innovative technologies, we’re excited to leverage their expertise for the advancement of our important drug development program.”

Selexis’ modular SUREtechnology Platform™ facilitates the rapid, stable, and cost-effective production of virtually any recombinant protein and provides seamless integration of the biologics development continuum, spanning discovery to commercialization.

About Selexis SA

Selexis SA, a JSR Life Sciences Company, is the global leader in cell line development with best-in-class modular technology and highly specialized solutions that enable the life sciences industry to rapidly discover, develop and commercialize innovative medicines and vaccines. Our global partners are utilizing Selexis technologies to advance more than 130 drug products in clinical development and the manufacture of seven commercial products. As part of a comprehensive drug development process, the Company’s technologies shorten development timelines and reduce manufacturing risks. More information is available at www.selexis.com.

About Igyxos

Igyxos’ mission is to develop new and innovative medical and pharmaceutical technologies in the field of human fertility. Igyxos is involved in all phases of development, from the discovery of promising targets to the identification of potential active compounds such as antibodies. The success of its €7.5 million Series A funding led by Bpifrance, through the FABS funds, alongside with Go Capital Amorçage II and Loire Valley Invest Funds managed by Go Capital and the Emergence Innovation II Fund managed by Sofimac Innovation, will allow Igyxos to develop its lead compound and reach clinical proof of concept. www.igyxos.com

###

FOR MORE INFORMATION
– Web               www.selexis.com
– LinkedIn        
www.linkedin.com/company/selexis-sa
– Twitter          
www.twitter.com/SelexisSA
– Facebook       
www.facebook.com/SelexisSA

Media Inquiries for Selexis
Mike Beyer
Sam Brown Inc.
+1 312-961-2502
mikebeyer@sambrown.com

Company Inquiries for Selexis
Robert Meister
Head, Corporate Communications
+1 602-953-1716
robert.meister@selexis.com

Company Inquiries for Igyxos
Pierre-Henry Longeray
CEO
+ 33 6 64 28 81 31 (mobile)
+ 33 2 47 42 76 32 (tel)
pierre-henry.longeray@igyxos.com

[1] Boivin J, Bunting L, Collins JA, Nygren KG (2007) International estimates of infertility prevalence and treatment-seeking: potential need and demand for infertility medical care. Hum Reprod 22: 1506–1512.

[2] Agarwal A, Mulgund A, Hamada A, Chyatte MR (2015) A unique view on male infertility around the globe. Reprod Biol Endocrinol 13: 37. 

Topics: Corporate

Crown Bio Signals Increased Investment in Digital Transformation with Appointment of New COO

San Diego, Calif - August, 6 2020 - Crown Bioscience today announces the appointment of John Gu as chief operations officer. Mr. Gu will provide leadership in promoting excellence across CrownBio’s global operations, leveraging his deep expertise in digitalization to drive productivity.

Topics: Corporate

New NAFLD/NASH Preclinical Model Data to be Presented at ADA 2020

San Diego, Calif – June 9, 2020 — Crown Bioscience today announced the presentation of new, proprietary NAFLD/NASH preclinical model development data. The data will be available at the American Diabetes Association (ADA) 80th Scientific Sessions, as well as CrownBio’s own complementary virtual event.

Topics: RR & IVD

MBL has concluded the license agreement regarding fully human monoclonal antibodies for four (4) infectious diseases.

NAGOYA, Japan - May 11, 2020 - Medical and Biological Laboratories Co., Ltd. (MBL), a JSR Life Sciences company, announces today that MBL has concluded the license agreement with China National Biotec Group Co., Ltd. (CNBG) of a subsidiary of China National Pharmaceutical Group Corporation (SINOPHARM) to comprehensively license fully human monoclonal antibodies generated by MBL for four (4) infectious diseases treatment. Under this license agreement, MBL confirms the development plan implemented by CNBG and its progress, and receives a license fee including running royalties as consideration for this license. CNBG
acquires the exclusive license to develop, manufacture, and sell those antibodies and to use related technical know-hows in China and the other Asian regions (excluding Japan), and begin development in China.

The fully human monoclonal antibodies were generated by using MBL’s basic technology of the
SPYMEG* or the phage display technology. The antibodies are expected to help in treating and
preventing pandemic infections including Influenza because of their broadly neutralizing activity.

MBL Launches New ELISA-based Companion Diagnostic Kit for Spinal Muscular Atrophy

NAGOYA, Japan - May 8, 2020 - Medical and Biological Laboratories Co., Ltd. (MBL), a JSR Life Sciences company, announced today that it has launched an in vitro diagnostic kit for the genetic disease Spinal Muscular Atrophy (SMA). The MEBCDX AAV9 test kit, which was licensed from Quest Diagnostics, was approved on April 27 by the Ministry of Health, Labour and Welfare (MHLW) as a companion diagnostic (CDx) kit for the SMA gene therapy ZolgensmaTM (onasemnogene abeparvovec-xioi) launched by Novartis International AG. The test kit will enable laboratory testing through LSI Medience Corporation starting today. 

Topics: RR & IVD

CrownBio Announces C-Suite Leadership Changes

San Diego, CA - April 14, 2020 - Crown Bioscience has announced the appointment of Jean-Pierre Wery, PhD as executive chairman of the board effective immediately. Dr. Wery will also serve as chief technology officer (CTO) for JSR Life Sciences, LLC.

Topics: Corporate

Medical & Biological Laboratories Co., Ltd. launches real time PCR-based assay kit products for SARS-CoV-2

NAGOYA, Japan - March 23, 2020 - Medical and Biological Laboratories Co., Ltd. (MBL), a JSR Life Sciences company, announced today that its subsidiary company, G&G Science Co., Ltd., has successfully completed development of a real-time PCR assay kit for “severe acute respiratory syndrome coronavirus 2” (SARS-CoV-2). The kit was evaluated with clinical samples provided by the National Institute of Infectious Diseases (NIID). NIID and the Japan Ministry of Health, Labour and Welfare (MHLW) today published that the results of testing with the kit corresponded 100 percent to those of the current NIID system on both positive and negative agreement rates. Therefore, starting immediately, the kit can be used not only for emergency testing being executed under the Infectious Diseases Control Law of Japan, but also for the clinical testing for the coverage of public medical insurance.

Topics: RR & IVD

JSR Life Sciences and GlycoSeLect Enter Licensing and Joint Development Agreement

Sunnyvale, CA, ‐ October 31, 2019 JSR Life Sciences announced today that it has signed a technology licensing and joint development agreement with Dublin, Ireland-based GlycoSeLect, which provides recombinant prokaryotic lectins (RPLs) that enable the selective isolation of glycosylated biomolecules.  The agreement will focus on the development of a glyco-affinity ligand and capture resin.

Topics: Bioprocess

PeptiDream and JSR Begin a Joint Development Program to Identify Peptides Applicable to Affinity Chromatography

TOKYO, JAPAN – September 20, 2019 - JSR Corporation and PeptiDream Inc. have agreed to begin a joint development program to identify peptides applicable to the affinity chromatography*1 process used in the purification of biopharmaceuticals such as antibody therapeutics.

Topics: Bioprocess

JSR Life Sciences, LLC Expands through East Coast Center of Excellence

Sunnyvale, CA – July 11, 2019 – JSR Life Sciences, LLC announced today that it has expanded its footprint and technical capabilities through the opening of its Applications Center of Excellence in Durham, NC.  The new facility provides state-of-the-art laboratory and work space for JSR’s Separations Sciences Group (SSG) to focus on applications development, customer support and training. 

Topics: Bioprocess

JSR Corporation Transfer of Representative Directors

JSR Corporation Transfer of Representative Directors Announcement 

Topics: Corporate

JSR Establishes US Headquarters for JSR Life Sciences and North American Holding Company

SUNNYVALE, CA – Mar. 14, 2019 – JSR announced today that it will establish a US headquarters for its biotechnology and life sciences focused businesses under the name JSR Life Sciences, LLC effective April 1, 2019.  The formation of JSR Life Sciences will centralize leadership and resources to support the company’s value proposition of driving innovation to provide a portfolio of integrated products, services and technologies to help partners develop and commercialize therapeutics and diagnostics that benefit global human health.

Topics: Corporate

Aspect Biosystems Announces Liver Tissue Collaboration with JSR

Vancouver, Canada - September 18, 2018 - Aspect Biosystems, a privately held biotechnology company focused on commercializing cutting-edge bioprinting technologies, is pleased to announce a new collaboration to develop human liver tissue with JSR Corporation, a leading materials supplier in a variety of technology driven markets. Through this collaboration, Aspect’s proprietary Lab-on-a-Printer™ 3D bioprinting platform and JSR’s advanced materials technology will be used to develop vascularized human liver lobules.  

Topics: Corporate

JSR Completes its Amsphere™ A3 Capacity Expansion

Leuven, Belgium – May 17, 2018 – JSR Life Sciences (JLS) is pleased to announce that it has completed its capacity expansion for production of its Amsphere™ A3 protein-A chromatography resin in Leuven, Belgium. The new facility has been built to the highest quality standards using state of the art engineering and is adjacent to JSR’s existing European operations, JSR Micro NV.  

Topics: Bioprocess

Oxford Performance Materials and JSR Corporation Announce Partnership to Advance OPM Technology Platform Throughout Asia

SOUTH WINDSOR, Conn. and TOKYO - May 14, 2018 - Oxford Performance Materials, Inc. (OPM), a leader in advanced materials science and high performance additive manufacturing (HPAM®), and Tokyo-based JSR Corporation (JSR), a leading materials supplier in a variety of technology driven markets, today announced a partnership to advance OPM’s poly-ether-ketone-ketone (PEKK)-based 3D-printed orthopedic devices and biomedical & dental materials businesses throughout Asia. 

Topics: Corporate

JSR has exclusively licensed intellectual property for the treatment and diagnosis of inflammatory bowel disease

Tokyo, Japan – January 30, 2018 – JSR Corporation has been granted an exclusive license for intellectual property from Keio University for the treatment and diagnosis of inflammatory bowel disease (IBD). JSR then granted exclusive licenses of the key intellectual property to BiomX Ltd., a microbiome drug discovery company developing customized phage therapies, to develop and commercialize phage therapies based on the intellectual property. 

Topics: RR & IVD

JSR Announces Acquisition of Crown Biosciences International

TOKYO – Dec. 20, 2017 – JSR Life Sciences (JLS) announced today that JSR Corporation has agreed to purchase Crown Bioscience International (TPEx: ticker 6554) at 12 Billion New Taiwan Dollar, a global drug discovery and development services company providing translational platforms to advanced oncology, inflammation, cardiovascular and metabolic disease research.  This acquisition marks JSR’s largest life sciences-focused investment to date, extending the company’s portfolio to include industry-leading contract research and development capabilities

Topics: Corporate

JSR Life Sciences Agrees to Acquire Pioneering Cell Line Developer Selexis SA and Integrate Selexis with KBI Biopharma, Inc.

JSR Life Sciences, the life-sciences focused division of JSR Corporation, will offer industry partners best-in-class CDMO services by complementing its commercial subsidiary KBI Biopharma with Selexis SA Technologies

Topics: Bioprocess

JSR Life Sciences Expands Manufacturing Capabilities at KBI Biopharma

Durham, NC - May 23, 2017 - JSR Life Sciences (JLS) today announced that KBI Biopharma (KBI), a subsidiary of JSR Corporation (JSR), is expanding its biopharmaceutical manufacturing capacity and capabilities at both its Durham, North Carolina and Boulder, Colorado facilities.  KBI is investing approximately $30M on the two site expansion projects, which will greatly enhance the offerings at each site and are scheduled for completion later this year.

Topics: Bioprocess

JSR Corporation Establishes JSR Life Sciences Division, Names North American Leader

April 14, 2016 – Sunnyvale, CA – JSR Life Sciences Division (JLS) today announced the formation and establishment of its global corporate headquarters in Sunnyvale, CA USA. Eric R. Johnson will assume responsibility of all operations as Senior Executive Officer and General Manager Life Sciences Division. JLS US headquarters will be responsible for all commercial business activities including strategic planning, customer support, marketing and product development oversight.

Topics: Corporate

Featured